AGEN News 2.55 Agenus Inc (AGEN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Agenus Inc (AGEN) 2.55 $AGEN

Agenus to Host Annual Meeting of Stockholders
Business Wire - Wed Apr 16, 10:45AM CDT
Agenus Inc. (NASDAQ: AGEN) invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Wednesday, April 23, 2014. The meeting will be held at the company's headquarters located at 3 Forbes Road, Lexington, MA 02421. Registration for attendees starts at 4:30 p.m. ET.

Positive Results on Intercept Pharma's OCA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 3:30PM CDT
Intercept Pharma announced positive additional data from the phase III study on obeticholic acid.

The Worst Biotech Failures of the Week
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 08, 8:30AM CDT
Things were tough all over last week as the biotechnology industry continued its month-long slide. It was also a rough week in the clinic as an unusual number of companies announced disappointing clinical results and trial stoppages. Amgen ...

Is Biotech in a Bubble? The Bear Case Explained
Chris Ahlstrand, The Motley Fool - Motley Fool - Fri Apr 04, 8:30AM CDT
The rumblings of a biotech bubble are getting louder as the Nasdaq Biotech Index has declined about 14% from its peak of $275.40 on February 25th. The recent volatility is a phenomenon that has not been seen in quite some time in the space. So is...

Glaxo Stops MAGE-A3 Lung Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 5:14PM CDT
Glaxo announced that it has decided to terminate the phase III MAGRIT study on its MAGE-A3 cancer immunotherapeutic.

Today’s Top Biotech Stories: MannKind, GSK, Myriad, and Alnylam
Leo Sun, The Motley Fool - Motley Fool - Wed Apr 02, 8:22AM CDT
Let's take a look a four stocks -- MannKind , GlaxoSmithKline , Myriad Genetics , and Alnylam Pharmaceuticals -- all of which could loom large in health care headlines this Wednesday morning. FDA advisory panel recommends the approval of...

Update on GSK'S MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-Small Cell Lung Cancer
Business Wire - Wed Apr 02, 1:01AM CDT
Agenus Inc. (Nasdaq: AGEN) today announced that GlaxoSmithKline's (NYSE: GSK) MAGRITi study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3ii cancer immunotherapeutic trial in non-small cell lung cancer (NSCLC) patients, which contains Agenus'QS-21 Stimulon(R) adjuvant, will be stopped. GSK announced that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment.

Agenus (AGEN) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 5:47AM CDT
Agenus (AGEN) Sees Hammer Chart Pattern: Time to Buy?

The Week's Worst Clinical Failures
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 1:30PM CDT
While there were plenty of winners last week, two losers stand out. The first failure belongs to GlaxoSmithKline . This giant is leading the industry with 20 new molecular entity approvals over the past six years. But its recent failure shows how...

Biotech Stock Roundup: GILD Letter Triggers Major Selloff - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 9:13AM CDT
Are the good days over for the biotech sector or is this just a correction?

Agenus to Present at the 4th Annual Cancer Immunotherapy Conference
Business Wire - Wed Mar 26, 6:00AM CDT
Agenus Inc. (Nasdaq: AGEN) today announced that Robert Stein, MD, PhD, Chief Scientific Officer of Agenus, will be presenting on Agenus' checkpoint modulator portfolio and immuno-oncology strategy at the 4th Annual Cancer Immunotherapy Conference at the New York Academy of Medicine in New York City. On March 27, 2014, a presentation on Checkpoint Modulators is scheduled for 8:30 am Eastern Time and a corporate presentation is scheduled for 2:15 pm Eastern Time.

These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.

Stock to Watch: Antigenics Down 10.2% (AGEN)
Comtex SmarTrend(R) - Mon Mar 24, 12:49PM CDT
Antigenics (NASDAQ:AGEN) is one of today's worst performing low-priced stocks, down 10.2% to $3.27 on 1.0x average daily volume. Thus far today, Antigenics has traded 1.3 million shares, vs. average volume of 1.3 million shares per day. The stock has underperformed the Dow (-10.2% to the Dow's -0.3%) and underperformed the S&P 500 (-10.2% to the S&P's -0.6%) during today's trading.

Why Agenus (AGEN) Might Be a Diamond in the Rough - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 7:46AM CDT
If you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider Agenus.

This Week in Biotech: Endocyte Doubles, Intercept Wobbles, and Geron Gets Smacked Again
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 22, 12:45PM CDT
With the  SPDR S&P Biotech Index  up  57% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...

Glaxo's MAGE-A3 Candidate Disappoints Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:36PM CDT
Glaxo announced disappointing data from the phase III MAGRIT study on its MAGE-A3 cancer immunotherapeutic.

Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'
at The Street - Fri Mar 21, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Guess and Lennar are big market movers
AP - Thu Mar 20, 4:29PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:

Why Agenus Inc. Shares Tumbled
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 20, 1:33PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Agenus , a biopharmaceutical company...

Why Agenus (AGEN) Is Down Big Today
at The Street - Thu Mar 20, 10:22AM CDT
Shares of Agenus (AGEN) fall on Thursday following the news that the latest round of Phase 3 non small cell lung immunotherapeutic trials had failed to meet its first or secondary co-primary endpoint.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Greenberg Traurig Builds Real Estate Bench Further

Updated Category News Views 71

Two real estate lawyers rarely move a market, but they can tell you where the legal work is getting sticky. Greenberg Traurig’s November 19 addition of Steven A. Fein and Kelsey Thayer is not some grand macroeconomic pronouncement, and nobody should pretend otherwise. It is, however, a pretty sensible read on the messy corners of commercial property finance: joint...

Continue Reading
Hydron’s Bailey Test Puts RNG Cost Claims to Real Work

Updated Category News Views 55

Landfill gas is messy stuff, which is exactly why Hydron Energy’s Bailey Landfill demonstration in Chilliwack deserves more attention than another clean-energy press release. The British Columbia company is putting its INTRUPTor™ gas-separation system into an operating environment alongside FortisBC and the City of Chilliwack, where the machinery has to deal with real...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 108

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
Birkenstock’s Athens Stores Put Brand Control to Work

Updated Category News Views 41

A 62-square-meter shop on Ermou Street can say plenty about a brand’s ambitions. Birkenstock is opening its first two Greek stores in Athens, moving beyond its existing wholesale and retail-partner presence with locations it can shape from the floorboards up. The first site at Ermou 18 is stated to have opened on November 12, 2026; the announcement itself is dated...

Continue Reading
AbbaDox Finds Follow-Up Scans Lost in the Shuffle

Updated Category News Views 163

A six-month recommendation has a nasty habit of disappearing beneath today’s emergencies. That is the unglamorous, important problem AbbaDox is trying to solve in outpatient radiology: not reading the scan, but making sure a future scan recommendation actually gets reviewed, ordered, and scheduled. For investors watching healthcare operations software, this is the sort...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 44

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 54

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
Visa CEDP Data Gaps Are Quietly Hammering Merchants

Updated Category News Views 100

Somewhere between a checkout button and settlement, an awful lot of money is apparently falling through a trapdoor. Verisave and Canyon Payments say 93% of the 180 merchant accounts they reviewed during one month missed Visa Commercial Enhanced Data Program discounts they could have received. The claimed savings left on the table topped $800,000 for that group in that...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 30

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 198

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Magnetron Solutions for Peak RF Performance

Updated Category News Views 129

Revolutionizing RF Power with Advanced Magnetron Transmitters In the realm of radio frequency (RF) technology, Diversified Technologies, Inc. (DTI) has unveiled a groundbreaking solid-state magnetron transmitter, which utilizes a novel Marx modulator. This innovative approach allows users to finely tune the pulse wave, enhancing overall performance and adaptability for...

Continue Reading
Lineage Inc. Strengthens Financial Agreements and Growth Potential

Updated Category News Views 142

Lineage Inc. Updates Financial Agreements for Greater Flexibility Lineage, Inc., a real estate investment trust recognized for its expertise in logistics, has made important changes to its financial agreements to bolster its financial standing. By adding more subsidiaries as obligors, the company demonstrates its flexibility and growth strategy. Recently, Lineage grabbed...

Continue Reading
Super League Achieves Major Financial Milestones in 2025

Updated Category News Views 394

Super League Reports Impressive Financial Growth Super League has recently showcased remarkable financial improvements, marking a significant turnaround in its operations. This comes on the heels of the company achieving a robust balance sheet powered by strategic investments, including a $20 million private placement and, notably, having zero debt. These developments not...

Continue Reading
Michael Lachmann's 'Spacetime Capsule' Documentary Now Streaming

Updated Category News Views 241

Michael Lachmann's Innovative Documentary Series The new documentary series, Spacetime Capsule, directed by British filmmaker Michael Lachmann, has recently premiered on popular Chinese video platforms. This captivating series, produced by China Review Studio, consists of three episodes that creatively employ the concept of a "spacetime capsule" to frame its narrative,...

Continue Reading
Innovative Leaders of Tomorrow: The 2025 TIME100 Next List

Updated Category News Views 395

TIME Introduces the Inspiring 2025 TIME100 Next List Tate McRae to Perform at the Upcoming TIME100 Next Event In a recent announcement, TIME has unveiled its exciting 2025 TIME100 Next list, spotlighting a diverse group of 100 emerging leaders from across the globe. These individuals are not only shaping the future but are also redefining leadership norms within their...

Continue Reading